SOFIE key facts
- Developer of molecular imaging probes and devices designed to offer radiopharmaceutical products for Vivo research purposes.
- It has raised $504.9M; the latest was PE Growth/Expansion ($450.0M) in May 2024.
- Notable investors include Tata Group, Trilantic North America, MRM Capital, Cycad Group.
- Status: Privately Held (backing).
Who backs SOFIE
4- ·Watch SOFIE: the Monday email on marks, rounds and moves
SOFIE funding rounds
No funding rounds for SOFIE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
SOFIE investors
4 investors are on record for SOFIE, including Tata Group, Trilantic North America, MRM Capital and Cycad Group.
About SOFIE
Developer of molecular imaging probes and devices designed to offer radiopharmaceutical products for Vivo research purposes. The company's devices help physicians to search throughout the body for tumors that will respond to drugs that target dCK, enabling caregivers to get access to theragnostic and innovative technologies for personalized healthcare and for more patient-specific treatment selection.
- Sector
- Healthcare
- HQ
- Dulles, VA, United States
- Founded
- 2008
- Employees
- 320
- Website
- sofie.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
SOFIE doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.